Send us a text🧠 Clinical Context:Hypertrophic obstructive cardiomyopathy (HOCM): Genetic disorder causing LVOT obstruction.Traditionally managed with BBs, CCBs, disopyramide… or surgery.💊 Drug: Mavacamten (Cardiac Myosin Inhibitor)Targets sarcomeric hypercontractility directly.FDA approved for NYHA Class II–III obstructive HCM.🧪 EXPLORER-HCM Trial:62-week follow-up:↓ LVOT gradient (resting & post-exercise).Improved NYHA class.↑ Peak oxygen consumption (VO₂).⚠️ Key Considerations:Follow-up echocardiograms required — risk of LVEF drop.Avoid negative inotropes.Can worsen HF if EF <55%.🧩 Clinical Takeaway:First disease-modifying med for obstructive HCM.Exercise no longer strictly off-limits — patients should be supervised and tailored.If surgery is needed, refer to high-volume HCM centers only.

Ver todos los episodios